Page 1879 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 108 Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses 1668.e3

94. MacDonald KP, Rowe V, Clouston AD, et al: Cytokine expanded 116. Wilhelm K, Ganesan J, Muller T, et al: Graft-versus-host disease
myeloid precursors function as regulatory antigen-presenting cells is enhanced by extracellular ATP activating P2X7R. Nat Med
and promote tolerance through IL-10-producing regulatory T cells. 16(12):1434–1438, 2010.
J Immunol 174:1841, 2005. 117. Jankovic D, Ganesan J, Bscheider M, et al: The Nlrp3 inflammasome
95. Banchereau J, Steinman RM: Dendritic cells and the control of immu- regulates acute graft-versus-host disease. J Exp Med 210:1899, 2013.
nity. Nature 392:245, 1998. 118. Toubai T, Hou G, Mathewson N, et al: Siglec-G-CD24 axis controls
96. Duffner UA, Maeda Y, Cooke KR, et al: Host dendritic cells alone the severity of graft-versus-host disease in mice. Blood 123:3512,
are sufficient to initiate acute graft-versus-host disease. J Immunol 2014.
172:7393, 2004. 119. Tawara I, Sun Y, Lewis EC, et al: Alpha-1-antitrypsin monotherapy
97. Sato K, Yamashita N, Baba M, et al: Regulatory dendritic cells protect reduces graft-versus-host disease after experimental allogeneic bone
mice from murine acute graft-versus-host disease and leukemia relapse. marrow transplantation. Proc Natl Acad Sci USA 109:564, 2012.
Immunity 18:367, 2003. 120. Brennan TV, Lin L, Huang X, et al: Heparan sulfate, an endogenous
98. Maeda Y, Reddy P, Lowler KP, et al: Critical role of host gammadelta TLR4 agonist, promotes acute GVHD after allogeneic stem cell trans-
T cells in experimental acute graft-versus-host disease. Blood 106:749, plantation. Blood 120:2899, 2012.
2005. 121. Jenq RR, Ubeda C, Taur Y, et al: Regulation of intestinal inflammation
99. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, et al: Vasoactive by microbiota following allogeneic bone marrow transplantation. J Exp
intestinal peptide induces regulatory dendritic cells that prevent acute Med 209(5):903, 2012.
graft-versus-host disease while maintaining the graft-versus-tumor 122. Eriguchi Y, Takashima S, Oka H, et al: Graft-versus-host disease dis-
response. Blood 107:3787, 2006. rupts intestinal microbial ecology by inhibiting Paneth cell production
100. Macdonald KP, Kuns RD, Rowe V, et al: Effector and regulatory T cell of alpha-defensins. Blood 120(1):223, 2012.
function is differentially regulated by RelB within antigen presenting 123. Holler E, Butzhammer P, Schmid K, et al: Metagenomic analysis of the
cells during GVHD. Blood 2007. stool microbiome in patients receiving allogeneic stem cell transplanta-
101. Paraiso KH, Ghansah T, Costello A, et al: Induced SHIP deficiency tion: loss of diversity is associated with use of systemic antibiotics
expands myeloid regulatory cells and abrogates graft-versus-host disease. and more pronounced in gastrointestinal graft-versus-host disease. Biol
J Immunol 178:2893, 2007. Blood Marrow Transplant 20(5):640, 2014.
102. Merad M, Hoffmann P, Ranheim E, et al: Depletion of host Langerhans 124. Korngold R, Sprent J: Negative selection of T cells causing lethal graft-
cells before transplantation of donor alloreactive T cells prevents skin versus-host disease across minor histocompatibility barriers. Role of the
graft-versus-host disease. Nat Med 10:510, 2004. H-2 complex. J Exp Med 151:1114, 1980.
103. Li H, Kaplan DH, Matte-Martone C, et al: Langerhans cells are not 125. Beilhack A, Schulz S, Baker J, et al: In vivo analyses of early events
required for graft-versus-host disease. Blood 117:697, 2011. in acute graft-versus-host disease reveal sequential infiltration of T-cell
104. Nachbaur D, Kircher B, Eisendle K, et al: Phenotype, function and subsets. Blood 106:1113, 2005.
chimaerism of monocyte-derived blood dendritic cells after allogeneic 126. Shlomchik WD: Antigen presentation in graft-vs-host disease. Exp
haematopoietic stem cell transplantation. Br J Haematol 123:119, 2003. Hematol 31:1187, 2003.
105. Toubai T, Tawara I, Sun Y, et al: Induction of acute GVHD by 127. Lechler R, Ng WF, Steinman RM: Dendritic cells in transplantation—
sex-mismatched H-Y antigens in the absence of functional radio- friend or foe? Immunity 14:357, 2001.
sensitive host hematopoietic-derived antigen-presenting cells. Blood 128. Sayegh MH, Carpenter CB: Role of indirect allorecognition in allograft
119(16):3844–3853, 2012. rejection. Int Rev Immunol 13:221, 1996.
106. Koyama M, Kuns RD, Olver SD, et al: Recipient nonhematopoietic 129. Kaplan DH, Anderson BE, McNiff JM, et al: Target antigens determine
antigen-presenting cells are sufficient to induce lethal acute graft-versus- graft-versus-host disease phenotype. J Immunol 173:5467, 2004.
host disease. Nat Med 18(1):135–142, 2012. 130. Anderson BE, McNiff JM, Jain D, et al: Distinct roles for donor- and
107. Li H, Demetris AJ, McNiff J, et al: Profound depletion of host host-derived antigen-presenting cells and costimulatory molecules in
conventional dendritic cells, plasmacytoid dendritic cells, and B murine chronic graft-versus-host disease: requirements depend on
cells does not prevent graft-versus-host disease induction. J Immunol target organ. Blood 105:2227, 2005.
188(8):3804–3811, 2012. 131. Appleman LJ, Boussiotis VA: T cell anergy and costimulation. Immunol
108. Toubai T, Mathewson N, Oravecz-Wilson K, et al: Host Rev 192:161, 2003.
CD8α+Dendritic Cells May Be a Key Factor for Separating Graft- 132. Sharpe AH, Freeman GJ: The B7-CD28 superfamily. Nat Rev Immunol
versus-Host Disease from Graft-versus-Leukemia. Biol Blood Marrow 2:116, 2002.
Transplant 21(4):775–776, 2015. 133. Bromley SK, Iaboni A, Davis SJ, et al: The immunological synapse and
109. Toubai T, Sun Y, Luker G, et al: Host-derived CD8+ dendritic cells CD28-CD80 interactions. Nat Immunol 2:1159, 2001.
are required for induction of optimal graft-versus-tumor responses 134. Dustin ML: Role of adhesion molecules in activation signaling in T
after experimental allogeneic bone marrow transplantation. Blood lymphocytes. J Clin Immunol 21:258, 2001.
121(20):4231–4241, 2013. 135. Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu
110. Koyama M, Cheong M, Markey KA, et al: Donor colonic CD103+ Rev Immunol 23:515, 2005.
dendritic cells determine the severity of acute graft-versus-host disease. 136. Barao I, Hanash AM, Hallett W, et al: Suppression of natural killer
+
+
J Exp Med 212(8):1303–1321, 2015. cell-mediated bone marrow cell rejection by CD4 CD25 regulatory T
111. Rowe V, Banovic T, MacDonald KP, et al: Host B cells produce IL-10 cells. Proc Natl Acad Sci USA 103:5460, 2006.
following TBI and attenuate acute GVHD after allogeneic bone marrow 137. Blazar BR, Taylor PA, Gray GS, et al: The role of T-cell subsets in
transplantation. Blood 108:2485, 2006. regulating the in vivo efficacy of CTLA4-Ig in preventing graft-
112. Matte-Martone C, Wang X, Anderson B, et al: Recipient B cells are versus-host disease in recipients of fully MHC or minor histocompat-
not required for graft-versus-host disease induction. Biol Blood Marrow ibility (miH) only disparate donor inocula. Transplantation 58:1422,
Transplant 16:1222, 2010. 1994.
113. Tawara I, Nieves E, Liu C, et al: Host basophils are dispensable for 138. Blazar BR, Korngold R, Vallera DA: Recent advances in graft-versus-
induction of donor T helper 2 cell differentiation and severity of host disease (GVHD) prevention. Immunol Rev 157:79, 1997.
experimental graft-versus-host disease. Biol Blood Marrow Transplant 139. Blazar BR, Boyer MW, Taylor PA, et al: The role of CD28:B7 in
2011. the persistent graft-vs-leukemia (GVL) effect of delayed post-BMT
114. Schwab L, Goroncy L, Palaniyandi S, et al: Neutrophil granulocytes splenocyte infusions in mice. Blood 86:115, 1995.
recruited upon translocation of intestinal bacteria enhance graft-versus- 140. Blazar BR, Kwon BS, Panoskaltsis-Mortari A, et al: Ligation of 4-1BB
host disease via tissue damage. Nat Med 20(6):648–654, 2014. (CDw137) regulates graft-versus-host disease, graft-versus-leukemia,
115. Magenau J, Reddy P: Next generation treatment of acute graft-versus- and graft rejection in allogeneic bone marrow transplant recipients.
host disease. Leukemia 28(12):2283–2291, 2014. J Immunol 166:3174, 2001.